Cargando…

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

BACKGROUND: The undetermined efficacy of the current standard-of-care neoadjuvant treatment, anthracycline/platinum-based chemotherapy, in patients with early-stage triple-negative breast cancer (TNBC) and germline BRCA mutations emphasizes the need for biomarker-targeted treatment, such as poly(ADP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Litton, Jennifer K, Beck, J Thaddeus, Jones, Jason M, Andersen, Jay, Blum, Joanne L, Mina, Lida A, Brig, Raymond, Danso, Michael, Yuan, Yuan, Abbattista, Antonello, Noonan, Kay, Niyazov, Alexander, Chakrabarti, Jayeta, Czibere, Akos, Symmans, William F, Telli, Melinda L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Breast Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546823/ https://www.ncbi.nlm.nih.gov/pubmed/37318349 http://dx.doi.org/10.1093/oncolo/oyad139

Ejemplares similares

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
por: Hurvitz, Sara A., et al.
Publicado: (2019)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
por: Blum, Joanne L., et al.
Publicado: (2022)

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
por: Litton, J. K., et al.
Publicado: (2017)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
por: Hoffman, Justin, et al.
Publicado: (2019)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors
por: Durairaj, Chandrasekar, et al.
Publicado: (2021)

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
por: Gruber, Joshua J., et al.
Publicado: (2022)

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study
por: Turner, Nicholas C., et al.
Publicado: (2023)

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment
por: Guo, Cen, et al.
Publicado: (2022)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022)

Quantitative background parenchymal enhancement and fibro-glandular density at breast MRI: Association with BRCA status
por: Goodburn, Rosie, et al.
Publicado: (2023)

RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
por: Zou, Denise, et al.
Publicado: (2021)

Improved characterization of sub-centimeter enhancing breast masses on MRI with radiomics and machine learning in BRCA mutation carriers
por: Lo Gullo, Roberto, et al.
Publicado: (2020)

Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers
por: Depypere, Herman, et al.
Publicado: (2021)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Fingerprinting Lymph Node Metastases
por: Symmans, W. Fraser, et al.
Publicado: (2008)

Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
por: Kotani, Haruru, et al.
Publicado: (2022)

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
por: Belz, Jodi E., et al.
Publicado: (2017)

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment
por: Litton, Jennifer K., et al.
Publicado: (2010)

Tattoo pigment mimicking axillary lymph node calcifications on mammography
por: Paul Litton, Tyler, et al.
Publicado: (2020)

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
por: Schram, Alison M., et al.
Publicado: (2022)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
por: Polyanskaya, Elizaveta, et al.
Publicado: (2023)

Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients
por: Culver, Julie O., et al.
Publicado: (2022)

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
por: Rugo, Hope S, et al.
Publicado: (2019)

A Retrospective Review of Arthroscopic Shaver Utilization in Adolescent Gynecomastia
por: Belza, Caitlyn C., et al.
Publicado: (2023)

Universal Germline-Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision-Making
por: Shelton, Charles, et al.
Publicado: (2023)

Cutaneous metastasectomy: Is there a role in breast cancer? A systematic review and overview of current treatment modalities
por: Huang, Samantha, et al.
Publicado: (2022)

Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib
por: Martinez, Ashley, et al.
Publicado: (2022)

Clinical value of radiomics and machine learning in breast ultrasound: a multicenter study for differential diagnosis of benign and malignant lesions
por: Romeo, Valeria, et al.
Publicado: (2021)

Evaluating Breast Reconstruction Reviews Using A Measurement Tool to Assess Systematic Reviews (AMSTAR)
por: Yuan, Morgan, et al.
Publicado: (2021)

Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy
Publicado: (2020)

“Spin” in Observational Studies in Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Systematic Review
por: Kim, Patrick J., et al.
Publicado: (2023)

Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
por: Zhang, Di, et al.
Publicado: (2021)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2007)

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases
por: Parkes, Amanda, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_43nq92uvdqrs5ljn6t0fas5bvo